Diabetes, Obesity & Metabolism, 23 (3), 754762
The SURMOUNT-5 trial, published in The New England Journal of Medicine , directly compared tirzepatide to semaglutide and found tirzepatide produced 47% greater relative weight loss at 72 weeks, 20.2% of body weight versus 13.7%
While there are no approved indications for using GLP-1 agonists specifically for the treatment of lipedema, these medications have shown numerous health benefits for women with dozens of medical conditions, such as Diabetes, Heart Disease, Kidney Disease, Parkinsons Disease, and Obesity, as well as for women without any existing medical problems
Do not schedule intense workouts, heavy meals, or high-stress activities within the first two to three hours
Strong reimbursement frameworks and the early adoption of cutting-edge GLP-1 therapies helped sustain market leadership
While there is no direct pharmacokinetic interaction documented between semaglutide and lisdexamfetaminemeaning one does not significantly alter the blood levels or metabolism of the otherthere are important pharmacodynamic considerations that clinicians and patients should be aware of
